Reported 2 days ago
William Blair has initiated coverage of Harrow, Inc. (NASDAQ:HROW) with an 'Outperform' rating and a price target of $63, highlighting its transition from a compounding pharmacy to a branded pharmaceutical company. The analyst emphasized the company's growth potential, particularly following the introduction of its affordability program, Vevye Access for All, and the recent reintroduction of Triesence, which could enhance product adoption and drive further growth.
Source: YAHOO